<DOC>
	<DOCNO>NCT01360840</DOCNO>
	<brief_summary>The primary objective trial evaluate clinical anti-tumor activity EMD 525797 administer 1-hour intravenous infusion every 3 week term progression free survival ( PFS ) time subject asymptomatic mildly symptomatic metastatic castrate-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>EMD 525797 Subjects With Asymptomatic Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate ( Gleason score ) Bisphosphonate treatment Stable , ongoing adequate testosterone suppression proven hypogonadal level testosterone ( less equal ) &lt; = 50 nanogram per deciliter [ ng/dL ] ) subject without surgical castration ( luteinizing hormonereleasing hormone antagonist agonist ) Other protocol define inclusion criterion could apply Prior chemotherapy , biologic therapy ( targeted therapy ) , experimental therapy mCRPC Chronic ongoing treatment opioids Acute pathologic fracture , spinal cord compression , hypercalcemia Screening Visceral metastasis , brain metastasis Radiotherapy bone lesion and/or orthopedic surgery pathologic fracture . Any kind major elective surgery within 30 day prior trial treatment Other protocol define exclusion criterion could apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Asymptomatic</keyword>
	<keyword>mildly symptomatic</keyword>
	<keyword>metastatic castrate-resistant prostate cancer</keyword>
	<keyword>mCRPC</keyword>
</DOC>